New Anti-CMV Therapies Post-Transplant: Merck & Co Leads The Pack
Executive Summary
Merck & Co’s investigational anti-CMV therapy letermovir is expected to be filed for approval later this year and could be the first of a new generation of anti-CMV therapies, following top-line Phase III data showing it reduced all-cause mortality in bone marrow transplant patients.
You may also be interested in...
Merck Plans Phase III Prevymis CMV Trials In Renal Transplant Patients
Merck & Co will start late-stage CMV prevention testing of first-in-class viral terminase complex inhibitor in renal transplant patients during the first half of 2018, following its launch for stem cell transplant recipients.
Keeping Track: A Massive Week Of Agency Approvals
The latest drug approval and development news from our US FDA Performance Tracker.
Finance Watch: NDA-Ready Impact Gets Commitment For Another $90m
Start-up Impact's new structured financing – its second fundraising event this month – will pay out in increments as fedratinib nears the market. Also, Ablynx closed its $200m US IPO; Chi-Med follow-on brings in $262m; and VCs gives Cydan $34m to launch new companies.